PDCD1 and acute graft versus host disease: Although prior PD-1 inhibitor might affect the outcome of subsequent allo-HSCT (27), two patients who underwent HSCT did not develop severe acute graft-versus-host disease, indicating that PD-1 blockade may be used as a bridge to allo-HSCT in patients with CAEBV.